630 related articles for article (PubMed ID: 32657795)
1. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Nicolò E; Zagami P; Curigliano G
Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
[TBL] [Abstract][Full Text] [Related]
2. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
3. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
4. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
5. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD; Miles D; Tsui CK; Zong Y
Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low.
Fan P; Xu K
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188849. PubMed ID: 36502928
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Abelman RO; Medford A; Spring L; Bardia A
Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug Conjugates for Breast Cancer Treatment.
Sheikh MS; Huang Y
Recent Pat Anticancer Drug Discov; 2022; 18(2):108-113. PubMed ID: 35909271
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Pondé N; Aftimos P; Piccart M
Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
[TBL] [Abstract][Full Text] [Related]
11. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
[TBL] [Abstract][Full Text] [Related]
12. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
13. [Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
;
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):913-927. PubMed ID: 36164692
[TBL] [Abstract][Full Text] [Related]
14. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
15. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
16. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
[TBL] [Abstract][Full Text] [Related]
17. Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer.
Rassy E; Rached L; Pistilli B
Breast; 2022 Dec; 66():217-226. PubMed ID: 36334569
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
19. Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer.
Chai M; Li L; Wu H; Liu Y; Yi Z; Yu H
Crit Rev Oncol Hematol; 2024 Mar; 195():104274. PubMed ID: 38295890
[TBL] [Abstract][Full Text] [Related]
20. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]